New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
06:01 EDTACORAcorda Therapeutics downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Acorda Therapeutics citing a lack of near-term catalysts and lowered its price target for shares to $33 from $37.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
16:30 EDTACORAcorda confirms Kyle Bass filed patent review requests
Subscribe for More Information
September 2, 2015
11:39 EDTACORBass denied request for review of Biogen multiple sclerosis drug patent
Subscribe for More Information
September 1, 2015
15:39 EDTACORAcorda Therapeutics initiated with a Buy at Aegis
Target $40.
10:05 EDTACOROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 8point3 Energy (CAFD) initiated with an Equal Weight at Barclays... AMAG Pharmaceuticals (AMAG) initiated with an Outperform at Raymond James... Acadia (ACHC) initiated with an Outperform at Leerink... Acorda Therapeutics (ACOR) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Strong Buy at Raymond James... Amedisys (AMED) initiated with an Outperform at Wells Fargo... Amgen (AMGN) initiated with a Market Perform at Raymond James... Amplify Snack Brands (BETR) initiated with a Neutral at Credit Suisse... BioMarin (BMRN) initiated with an Outperform at Raymond James... Biogen (BIIB) initiated with a Strong Buy at Raymond James... Celgene (CELG) initiated with a Strong Buy at Raymond James... CoreLogic (CLGX) initiated with a Neutral at SunTrust... Digi International (DGII) initiated with an Overweight at Stephens... First Solar (FSLR) initiated with an Overweight at Barclays... LHC Group (LHCG) initiated with an Outperform at Wells Fargo... Lancaster Colony (LANC) initiated with a Buy at BB&T... McCormick (MKC) initiated with a Buy at BB&T... NephroGenex (NRX) initiated with a Buy at H.C. Wainwright... Omega Protein (OME) initiated with a Hold at BB&T... Preferred Apartment (APTS) initiated with an Outperform at FBR Capital... Qorvo (QRVO) initiated with an Outperform at CLSA... Regeneron (REGN) initiated with an Outperform at Raymond James... Skyworks (SWKS) initiated with an Outperform at CLSA... SunPower (SPWR) initiated with an Equal Weight at Barclays... TESARO (TSRO) initiated with a Strong Buy at Raymond James... Ultragenyx (RARE) initiated with an Outperform at Raymond James... VEREIT (VER) initiated with a Buy at Goldman... Westmoreland (WLB) initiated with an Outperform at BMO Capital.
August 31, 2015
19:24 EDTACORAcorda Therapeutics initiated with a Market Perform at Raymond James
Subscribe for More Information
August 25, 2015
16:43 EDTACOROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
09:13 EDTACOROn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTACORAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
August 24, 2015
18:55 EDTACOROn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTACORJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
17:45 EDTACORAcorda Therapeutics up 31.2% after PTAB denies both IPRs of Ampyra patents
Subscribe for More Information
17:44 EDTACORAcorda Therapeutics announces PTAB denies both IPRs of Ampyra patents
Acorda Therapeutics announced that the United States Patent and Trademark Office, or USPTO, Patent Trials and Appeal Board. or PTAB, will not institute the inter partes review, or IPR, of U.S. Patent Nos. 8,663,685 and 8,007,826. The '685 and '826 patents are two of five Orange Book-listed patents that apply to Ampyra Extended Release Tablets, 10 mg, a novel treatment for multiple sclerosis developed by Acorda. Ampyra is a standard of care for improving walking in MS. The '685 and '826 patents are set to expire in 2025 and 2027, respectively.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use